🚀 VC round data is live in beta, check it out!
Kala Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kala Bio and similar public comparables like Agenus, Hamlet BioPharma, Precision BioSciences, Immunic and more.
Kala Bio Overview
About Kala Bio
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Founded
2009
HQ
Employees
43
Website
Sectors
Financials (FY)
EV
$179M
Kala Bio Financials
Kala Bio reported last fiscal year revenue of — and negative EBITDA of ($32M).
In the same fiscal year, Kala Bio generated ($32M) in EBITDA losses and had net loss of ($39M).
Revenue (LTM)
Kala Bio P&L
In the most recent fiscal year, Kala Bio reported revenue of — and EBITDA of ($32M).
Kala Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($32M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($39M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kala Bio Stock Performance
Kala Bio has current market cap of $171M, and enterprise value of $179M.
Market Cap Evolution
Kala Bio's stock price is $0.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $179M | $171M | 5.3% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKala Bio Valuation Multiples
Kala Bio trades at (5.5x) EV/EBITDA.
EV / Revenue (LTM)
Kala Bio Financial Valuation Multiples
As of April 11, 2026, Kala Bio has market cap of $171M and EV of $179M.
Equity research analysts estimate Kala Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kala Bio has a P/E ratio of (4.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $171M | XXX | $171M | XXX | XXX | XXX |
| EV (current) | $179M | XXX | $179M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.2x) | XXX | XXX | XXX |
| P/E | — | XXX | (4.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kala Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kala Bio Margins & Growth Rates
Kala Bio's revenue in the last fiscal year grew by —.
Kala Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
Kala Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (10%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kala Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Agenus | XXX | XXX | XXX | XXX | XXX | XXX |
| Hamlet BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Precision BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunic | XXX | XXX | XXX | XXX | XXX | XXX |
| Nkarta | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kala Bio M&A Activity
Kala Bio acquired XXX companies to date.
Last acquisition by Kala Bio was on XXXXXXXX, XXXXX. Kala Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kala Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKala Bio Investment Activity
Kala Bio invested in XXX companies to date.
Kala Bio made its latest investment on XXXXXXXX, XXXXX. Kala Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kala Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kala Bio
| When was Kala Bio founded? | Kala Bio was founded in 2009. |
| Where is Kala Bio headquartered? | Kala Bio is headquartered in United States. |
| How many employees does Kala Bio have? | As of today, Kala Bio has over 43 employees. |
| Who is the CEO of Kala Bio? | Kala Bio's CEO is Avi Minkowitz. |
| Is Kala Bio publicly listed? | Yes, Kala Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Kala Bio? | Kala Bio trades under KALA ticker. |
| When did Kala Bio go public? | Kala Bio went public in 2017. |
| Who are competitors of Kala Bio? | Kala Bio main competitors are Agenus, Hamlet BioPharma, Precision BioSciences, Immunic. |
| What is the current market cap of Kala Bio? | Kala Bio's current market cap is $171M. |
| Is Kala Bio profitable? | No, Kala Bio is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.